Improved overall survival in melanoma with combined dabrafenib and trametinib

New England Journal of Medicine

Volumn 372, Issue 1, 2015, Pages 30-39

  Robert, Caroline ^a   Karaszewska, Boguslawa ^d   Schachter, Jacob ^g   Rutkowski, Piotr ^e   Mackiewicz, Andrzej ^f   Stroiakovski, Daniil ^h,i   Lichinitser, Michael ^j   Dummer, Reinhard ^k   Grange, Florent ^b   Mortier, Laurent ^c   Chiarion Sileni, Vanna ^l   Drucis, Kamil ^o   Krajsova, Ivana ^m   Hauschild, Axel ⁿ   Lorigan, Paul ^p   Wolter, Pascal ^r   Long, Georgina V ^t   Flaherty, Keith ^v   Nathan, Paul ^s   Ribas, Antoni ^t,u   Martin, Anne Marie ^q   Sun, Peng ^v   Crist, Wendy ^v   Legos, Jeff ^v   Rubin, Stephen D ^v   Little, Shonda M ^v   Schadendorf, Dirk ^v   more..

^a Universite Paris Sud   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Przychodnia Lekarska KOMED   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ Moscow Municipal Oncology Hospital #62   (Russian Federation)

^j Cancer Research Center   (Russian Federation)

^k UNIVERSITY OF ZURICH   (Switzerland)

^l VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o UNIVERSITY HOSPITAL ESSEN   (Germany)

^p CHRISTIE HOSPITAL   (United Kingdom)

^q MOUNT VERNON CANCER CENTRE   (United Kingdom)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^s UNIVERSITY OF SYDNEY   (Australia)

^t MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ADULT; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILL; CHORIORETINOPATHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENE MUTATION; HAND FOOT SYNDROME; HAZARD RATIO; HEADACHE; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MONOTHERAPY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN CARCINOMA; SKIN PAPILLOMA; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; VOMITING; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; SECONDARY; SKIN NEOPLASMS; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMIDAZOLES; INDOLES; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84920394727     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1412690     Document Type: Article

References (28)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
2. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated meta-static melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
3. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011;364:772-4.
4. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4:80-93.
5. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4:94-109.
6. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
7. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011;23:177-82.
8. Carnahan J, Beltran PJ, Babij C, et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010;9:2399-410.
9. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-21.
10. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-7.
11. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
12. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
13. Long GV, Stroyakovskiy DL, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877-88.
14. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-76.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
17. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
18. Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res 2014;20:2035-43.
19. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-9.
20. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
21. Erratum, N Engl J Med 2010;363:1290.
22. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
23. Long GV, Stroyakovsky DL, Gogas H, et al. COMBI-d: a randomized, double-blinded, Phase III study comparing the combination of dabrafenib and tra-metinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. J Clin Oncol 2014;32:Suppl. abstract.
24. Corcoran RB, Dias-Santagata D, Ber-gethon K, Iafrate AJ, Settleman J, Engel-man JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3:ra84.
25. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
26. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012;11:909-20.
27. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106:20411-6.
28. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72.